Do analysts prefer ESLA or BIVI?

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,006.19%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Estrella Immunopharma is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ESLA or BIVI?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is ESLA or BIVI more profitable?

Estrella Immunopharma's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% BioVie N/A -101.15% -90.18%

Does the media refer more to ESLA or BIVI?

In the previous week, BioVie had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for BioVie and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.62 beat BioVie's score of 0.11 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioVie 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, QNCX or BIVI?

BioVie is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is QNCX or BIVI more profitable?

Quince Therapeutics' return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% BioVie N/A -101.15% -90.18%

Does the media refer more to QNCX or BIVI?

In the previous week, BioVie had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for BioVie and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat BioVie's score of 0.11 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BIVI or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIVI or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% BeyondSpring N/A N/A -14.00%

Does the media favor BIVI or BYSI?

In the previous week, BioVie had 1 more articles in the media than BeyondSpring. MarketBeat recorded 7 mentions for BioVie and 6 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.63 beat BioVie's score of 0.11 indicating that BeyondSpring is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IZTC or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, IZTC or BIVI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is IZTC or BIVI more profitable?

Invizyne Technologies' return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A BioVie N/A -101.15% -90.18%

Do analysts prefer BIVI or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BIVI or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is BIVI or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Genenta Science N/A N/A N/A

BioVie (BIVI) Competitors

$1.40 -0.16 (-10.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 -0.13 (-9.00%)

As of 07:59 PM Eastern

Compare

BIVI vs. ESLA, QNCX, BYSI, IZTC, and GNTA

Should you buy BioVie stock or one of its competitors? BioVie's main competitors and comparable companies include Estrella Immunopharma (ESLA), Quince Therapeutics (QNCX), BeyondSpring (BYSI), Invizyne Technologies (IZTC), and Genenta Science (GNTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioVie compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

In the previous week, BioVie had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for BioVie and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.62 beat BioVie's score of 0.11 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Estrella Immunopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, BioVie has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,006.19%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Estrella Immunopharma is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Estrella Immunopharma's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
BioVie	N/A	-101.15%	-90.18%

Summary

Estrella Immunopharma beats BioVie on 9 of the 13 factors compared between the two stocks.

How does BioVie compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

BioVie is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Quince Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, BioVie has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Quince Therapeutics' return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
BioVie	N/A	-101.15%	-90.18%

Quince Therapeutics presently has a consensus price target of $310.50, suggesting a potential upside of 812.16%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Quince Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioVie had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for BioVie and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat BioVie's score of 0.11 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats BioVie on 11 of the 14 factors compared between the two stocks.

How does BioVie compare to BeyondSpring?

BioVie (NASDAQ:BIVI) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, BioVie had 1 more articles in the media than BeyondSpring. MarketBeat recorded 7 mentions for BioVie and 6 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.63 beat BioVie's score of 0.11 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeyondSpring has higher revenue and earnings than BioVie. BeyondSpring is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
BeyondSpring	$1.75M	19.72	-$1.01M	-$0.14	N/A

4.6% of BioVie shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
BeyondSpring	N/A	N/A	-14.00%

BioVie has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Summary

BeyondSpring beats BioVie on 8 of the 11 factors compared between the two stocks.

How does BioVie compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

4.6% of BioVie shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Invizyne Technologies' return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
BioVie	N/A	-101.15%	-90.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioVie had 7 more articles in the media than Invizyne Technologies. MarketBeat recorded 7 mentions for BioVie and 0 mentions for Invizyne Technologies. BioVie's average media sentiment score of 0.11 beat Invizyne Technologies' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
BioVie	Neutral

Summary

BioVie beats Invizyne Technologies on 5 of the 7 factors compared between the two stocks.

How does BioVie compare to Genenta Science?

BioVie (NASDAQ:BIVI) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Genenta Science's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Genenta Science	N/A	N/A	N/A

4.6% of BioVie shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioVie had 6 more articles in the media than Genenta Science. MarketBeat recorded 7 mentions for BioVie and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat BioVie's score of 0.11 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Neutral
Genenta Science	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

BioVie has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Genenta Science beats BioVie on 7 of the 8 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.56M	$3.71B	$6.97B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-0.57	10.68	269.86	25.30
Price / Sales	N/A	1,305.14	601.47	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.14	17.49	13.08	6.33
Net Income	-$17.54M	-$13.32M	$3.45B	$347.70M
7 Day Performance	40.10%	1.74%	1.12%	1.07%
1 Month Performance	-11.39%	1.60%	1.79%	1.03%
1 Year Performance	-15.66%	56.43%	67.69%	20.77%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.2891 of 5 stars	$1.40 -10.3%	N/A	-8.2%	$11.77M	N/A	N/A	10	Earnings Report Gap Down
ESLA Estrella Immunopharma	2.6601 of 5 stars	$0.76 +5.2%	$8.00 +952.6%	-14.7%	$32.70M	N/A	N/A	N/A	Earnings Report Analyst Downgrade
QNCX Quince Therapeutics	2.9895 of 5 stars	$31.42 +2.5%	$568.40 +1,709.0%	-90.6%	$32.59M	N/A	N/A	60	News Coverage Earnings Report Analyst Upgrade
BYSI BeyondSpring	0.1491 of 5 stars	$0.79 +0.5%	N/A	-50.2%	$32.49M	$1.75M	N/A	80	News Coverage Earnings Report Gap Down
IZTC Invizyne Technologies	N/A	$5.11 -1.2%	N/A	-42.6%	$31.92M	N/A	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. ESLA, QNCX, BYSI, IZTC, and GNTA

How does BioVie compare to Estrella Immunopharma?

Summary

How does BioVie compare to Quince Therapeutics?

Summary

How does BioVie compare to BeyondSpring?

Summary

How does BioVie compare to Invizyne Technologies?

Summary

How does BioVie compare to Genenta Science?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. ESLA, QNCX, BYSI, IZTC, and GNTA

How does BioVie compare to Estrella Immunopharma?

Which has better earnings and valuation, ESLA or BIVI?

Does the media refer more to ESLA or BIVI?

Do institutionals and insiders hold more shares of ESLA or BIVI?

Which has more volatility and risk, ESLA or BIVI?

Do analysts prefer ESLA or BIVI?

Is ESLA or BIVI more profitable?

Summary

How does BioVie compare to Quince Therapeutics?

Which has higher valuation and earnings, QNCX or BIVI?

Which has more volatility & risk, QNCX or BIVI?

Is QNCX or BIVI more profitable?

Do analysts prefer QNCX or BIVI?

Does the media refer more to QNCX or BIVI?

Do insiders and institutionals hold more shares of QNCX or BIVI?

Summary

How does BioVie compare to BeyondSpring?

Does the media favor BIVI or BYSI?

Which has higher valuation and earnings, BIVI or BYSI?

Do insiders & institutionals have more ownership in BIVI or BYSI?

Do analysts rate BIVI or BYSI?

Is BIVI or BYSI more profitable?

Which has more risk and volatility, BIVI or BYSI?

Summary

How does BioVie compare to Invizyne Technologies?

Do institutionals and insiders hold more shares of IZTC or BIVI?

Which has stronger valuation & earnings, IZTC or BIVI?

Is IZTC or BIVI more profitable?

Do analysts rate IZTC or BIVI?

Does the media prefer IZTC or BIVI?

Summary

How does BioVie compare to Genenta Science?

Is BIVI or GNTA more profitable?

Do institutionals & insiders hold more shares of BIVI or GNTA?

Do analysts prefer BIVI or GNTA?

Does the media favor BIVI or GNTA?

Which has higher earnings & valuation, BIVI or GNTA?

Which has more volatility and risk, BIVI or GNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools